Blood test may help some ANCA patients skip unnecessary drugs
NCT ID NCT03906227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a specific type of immune cell (CD5+ regulatory B cells) can predict relapse risk in people with ANCA vasculitis, a rare autoimmune disease that damages blood vessels. Researchers aimed to see if patients with normal levels of these cells after initial treatment could safely stop maintenance therapy. The study was terminated early with only 9 participants, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-7155, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Can a new drug tame vasculitis with fewer side effects?
- Engineered immune cells take aim at autoimmune kidney diseases
- Could a diabetes drug shield kidneys from autoimmune attack?
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- New tool could predict who will suffer from steroid side effects